lyophilized powder raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-11-10 and is reviewed periodically as new material appears.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Meanwhile, Pakistani officials said that they had put forward three core demands to Taliban representatives: that Afghanistan formally designate Tehreek-e-Taliban Pakistan (TTP) as a terrorist organisation, dismantle its infrastructure, and provide verifiable proof of these actions. Pakistani officials also said that military operations in Afghanistan would continue until militant safe havens there were eliminated. Five policemen were injured in an IED attack by TTP in Lakki Marwat District.
Historically, it was common to store mutton or beef joints at room temperature for extended periods. However, after the invention of refrigeration, hanging sides of beef in large coolers for a few weeks as part of the processing became the standard.
Cobimetinib, sold under the brand name Cotellic, is an anti-cancer medication used to treat melanoma and histiocytic neoplasms. Cobimetinib is a MEK inhibitor. Cobimetinib is marketed by Genentech. The most common side effects include diarrhea, rash, nausea (feeling sick), vomiting, pyrexia (fever), photosensitivity (light sensitivity) reaction, abnormal results for certain liver function tests (increased levels of alanine aminotransferase, aspartate aminotransferase) and abnormal results for an enzyme related to muscle breakdown (creatine phosphokinase). Cobimetinib was approved for medical use in the United States in November 2015.
== Temperature instrumentation == Oil, gas and petrochemical processes are undertaken at specific temperatures. Measurement of temperature of fluids in the petrochemical industry is undertaken by temperature elements (TE). These can be Thermocouples or Platinum Resistance Temperature Detectors (RTDs). The latter are used for their good temperature response. Local temperature indicators (TI) are located on the inlet and outlet streams of heat exchangers to monitor the performance of the exchanger. In industrial applications gaseous or liquid fluids may be heated or cooled. This duty is undertaken in a heat exchanger, whereby the fluid is heated or cooled by heat transfer with a second fluid such as water, glycol, hot oil or another process fluid (the heating or cooling medium). Temperature control is used to maintain the desired temperature of the first fluid. A temperature sensor transmitter (TT) is located in the first fluid at its outlet from the heat exchanger. This measured temperature is fed to the temperature controller (TIC) where it is compared to the desired set point temperature. The output of the controller, which is related to the difference between the measured variable and the set point, is fed to a control valve (TCV) in the second fluid to adjust the flow of the heating or cooling medium. In the case of a fluid being cooled, if the temperature of the fluid rises the temperature controller acts to open the TCV increasing the flow of the cooling medium which increases the heat transfer and reduces the temperature of the first fluid.
The images produced through radiographic procedures are used for interpretation by radiologists, and depending on their education, training, and the regulations of the country in which they practice, radiographers in some regions also have an extended role in image interpretation and reporting.
Sources: en.wikipedia.org
This follows an exchange in the House during PMQs when Starmer, answering a question from the leader of the opposition, Kemi Badenoch, said that "two of her predecessors had convictions for breaking the Covid rules". Although the former Conservative prime ministers, Johnson and Rishi Sunak had received fixed penalty notices for breaking Covid-19 regulations, neither had any criminal convictions. Scottish Finance Secretary Shona Robison delivers the 2024 budget, which includes planned changes to taxation and a pledge to scrap the two child benefit cap in Scotland. Welsh Conservative leader Andrew RT Davies tells BBC News Wales there has been "plotting" among Conservative Senedd members to oust him since April. Secretary of State for Northern Ireland Hilary Benn begins the process of repealing the controversial Legacy Act. 27-year-old Sam Smith is announced as the new leader of Nottinghamshire County Council. Karen Kilgour, leader of Newcastle City Council, faces a vote of no confidence. 5 December – Starmer delivers a major speech in which he sets out six objectives which he says "give the British people the power to hold our feet to the fire"; the objectives cover the economy, housebuilding, the NHS, policing, pre-school education and green energy. Questions are raised over whether Henry Tufnell, the MP for Mid and South Pembrokeshire, gave his parents advanced knowledge of plans to change inheritance tax rules after they transferred ownership of farm land to one of their sons days before the budget.
It is important for MADD patients to maintain strength and fitness without exercising or working to exhaustion. Learning this balance may be more difficult than normally, as muscle pain and fatigue may be perceived differently from normal individuals. Symptomatic relief from the effects of MADD may sometimes be achieved by administering ribose orally at a dose of approximately 10 grams per 100 pounds (0.2 g/kg) of body weight per day, and exercise modulation as appropriate. Taken hourly, ribose provides a direct but limited source of energy for the cells. Patients with myoadenylate deaminase deficiency do not retain ribose during heavy exercise, so supplementation may be required to rebuild levels of ATP. Creatine monohydrate could also be helpful for AMPD patients, as it provides an alternative source of energy for anaerobic muscle tissue and was found to be helpful in the treatment of other, unrelated muscular myopathies. Inborn Errors of Metabolism Metabolic Myopathies Purine Nucleotide Cycle
Pu-239 is produced artificially in nuclear reactors when a neutron is absorbed by U-238, forming U-239, which then decays in a rapid two-step process into Pu-239. It can then be separated from the uranium in a nuclear reprocessing plant. Weapons-grade plutonium is defined as being predominantly Pu-239, typically about 93% Pu-239. Pu-240 is produced when Pu-239 absorbs an additional neutron and fails to fission. Pu-240 and Pu-239 are not separated by reprocessing. Pu-240 has a high rate of spontaneous fission, which can cause a nuclear weapon to pre-detonate, producing a fizzle. This makes plutonium unsuitable for use in gun-type nuclear weapons. To reduce the concentration of Pu-240 in the plutonium produced, weapons program plutonium production reactors (e.g. B Reactor) irradiate the uranium for a far shorter time than is normal for a nuclear power reactor. More precisely, weapons-grade plutonium is obtained from uranium irradiated to a low burnup. This represents a fundamental difference between these two types of reactor. In a nuclear power station, high burnup is desirable. Power stations such as the obsolete British Magnox and French UNGG reactors, which were designed to produce either electricity or weapons material, were operated at low power levels with frequent fuel changes using online refuelling to produce weapons-grade plutonium. Such operation is not possible with the light water reactors most commonly used to produce electric power. In these the reactor must be shut down and the pressure vessel disassembled to gain access to the irradiated fuel.
== History == It was developed by Boehringer Ingelheim, patented in 2005, and is co-marketed by Eli Lilly and Company. For cardiovascular death, the FDA based its decision on a postmarketing study it required when it approved empagliflozin in 2014, as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. Empagliflozin was studied in a postmarket clinical trial of more than 7,000 participants with type 2 diabetes and cardiovascular disease. In the trial, empagliflozin was shown to reduce the risk of cardiovascular death compared to a placebo when added to standard of care therapies for diabetes and atherosclerotic cardiovascular disease. For heart failure, the safety and effectiveness of empagliflozin were evaluated by the FDA as an adjunct to standard of care therapy in a randomized, double-blind, international trial comparing 2,997 participants who received empagliflozin, 10 mg, once daily to 2,991 participants who received the placebo. The main efficacy measurement was the time to death from cardiovascular causes or need to be hospitalized for heart failure. Of the individuals who received empagliflozin for an average of about two years, 14% died from cardiovascular causes or were hospitalized for heart failure, compared to 17% of the participants who received the placebo. This benefit was mostly attributable to fewer participants being hospitalized for heart failure. The FDA granted the application for empagliflozin priority review, and approved the additional indication of heart failure in 2022.
It has also been discovered that mRNA secondary structure is important for cell processes such as transcript stability and translation. The general idea is that the functional domains of mRNA fold upon each other, while the start and stop codon regions generally are more relaxed, which could aid in the signaling of initiation and termination in translation. If the oncoming ribosome pauses because of a knot in the RNA, then the polypeptide could potentially have enough time to fold into a non-native structure before the tRNA molecule can add another amino acid. Silent mutations may also affect splicing, or transcriptional control.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.